← DiscoverAI PREDICTION · 3-MONTH VIEW
IN
INSM
XNASInsmed, Inc.
Mkt Cap $30.2BPHARMACEUTICAL PREPARATIONS
FUNDAMENTALS
P/S
24.32EV/EBITDA
-33.73P/B
36.52EPS (TTM)
$-4.01ROE
-115.5%ROA
-41.6%FCF
$-807.7MMKT CAP
$27.7BTECHNICAL ANALYSIS
Mixed
RSI-14
57.8
Neutral
MACD
4.270
Bearish
SMA-50
$-1.00
$-1.00
SMA-200
$-1.00
$-1.00
BOLL %B
0.51
Within bands
ATR-14
$4.54
RVOL
0.87x
Normal
MOMENTUM
+6.5%
10d +0.4% / 30d +18.1%
4 strategies recently took profit here (avg +26.5%) — the move may have already played out.
▲Strong edge over the market
INSM holds a similar standing over 1 and 3 months.
WHERE IT RANKS · vs 2,142 names
20-DAY
▲Top 7%#151
60-DAY
▲#1
TYPICAL 3-MO RANGE · vs S&P 500
+0.3%leans upper+1.4%
▸ Horizon detail
20dTop 7%
60d#1
1y+analyst mean$205.17+63.0%
⚡ AI INSIGHT
Our model reads INSM as strong both near-term and over the next few months. Analysts agree (97% Buy) — the bull case lines up.
RECENT CATALYSTS
- ANLSTJP Morgan main26d
- ANLSTTruist Securities reit26d
REVENUE & GROWTH
$425M
Revenue
+0.4%
QoQ
+3.0%
YoY
Gross Margin
0.8%Expanding
ANALYST CONSENSUS
97% Buy
29 Buy1 Hold0 Sell
Low
$171
Mean
$205
High
$255
SHORT & FLOAT
Free Float
98.0%
2.7 days to cover.
Latest Headlines
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
GlobeNewswire Inc.8/31/2026
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Zacks Investment Research8/31/2026
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Zacks Investment Research8/27/2026
Alger Mid Cap 40 ETF Q2 2026 Portfolio Review
SeekingAlpha8/25/2026
Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance
SeekingAlpha8/23/2026